Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy.

Han H, Jain AD, Truica MI, Izquierdo-Ferrer J, Anker JF, Lysy B, Sagar V, Luan Y, Chalmers ZR, Unno K, Mok H, Vatapalli R, Yoo YA, Rodriguez Y, Kandela I, Parker JB, Chakravarti D, Mishra RK, Schiltz GE, Abdulkadir SA.

Cancer Cell. 2019 Nov 11;36(5):483-497.e15. doi: 10.1016/j.ccell.2019.10.001. Epub 2019 Oct 31.

PMID:
31679823
2.

EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cells.

Sagar V, Vatapalli R, Lysy B, Pamarthy S, Anker JF, Rodriguez Y, Han H, Unno K, Stadler WM, Catalona WJ, Hussain M, Gill PS, Abdulkadir SA.

Cell Death Dis. 2019 Oct 22;10(11):801. doi: 10.1038/s41419-019-2042-y.

3.

Nivolumab in Metastatic Adrenocortical Carcinoma: Results of a Phase 2 Trial.

Carneiro BA, Konda B, Costa RB, Costa RLB, Sagar V, Gursel DB, Kirschner LS, Chae YK, Abdulkadir SA, Rademaker A, Mahalingam D, Shah MH, Giles FJ.

J Clin Endocrinol Metab. 2019 Dec 1;104(12):6193-6200. doi: 10.1210/jc.2019-00600.

PMID:
31276163
4.

Palladium-catalyzed coupling reactions on functionalized 2-trifluoromethyl-4-chromenone scaffolds. Synthesis of highly functionalized trifluoromethyl-heterocycles.

Izquierdo J, Jain AD, Abdulkadir SA, Schiltz GE.

Synthesis (Stuttg). 2019 Mar;51(6):1342-1352. doi: 10.1055/s-0037-1610669.

5.

Organoids Increase the Predictive Value of in vitro Cancer Chemoprevention Studies for in vivo Outcome.

Njoroge RN, Vatapalli RJ, Abdulkadir SA.

Front Oncol. 2019 Feb 20;9:77. doi: 10.3389/fonc.2019.00077. eCollection 2019.

6.

Prostate Stroma Increases the Viability and Maintains the Branching Phenotype of Human Prostate Organoids.

Richards Z, McCray T, Marsili J, Zenner ML, Manlucu JT, Garcia J, Kajdacsy-Balla A, Murray M, Voisine C, Murphy AB, Abdulkadir SA, Prins GS, Nonn L.

iScience. 2019 Feb 22;12:304-317. doi: 10.1016/j.isci.2019.01.028. Epub 2019 Jan 23.

7.

Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression.

Song B, Park SH, Zhao JC, Fong KW, Li S, Lee Y, Yang YA, Sridhar S, Lu X, Abdulkadir SA, Vessella RL, Morrissey C, Kuzel TM, Catalona W, Yang X, Yu J.

J Clin Invest. 2019 Feb 1;129(2):569-582. doi: 10.1172/JCI122367. Epub 2018 Dec 18.

8.

The Role of Castration-Resistant Bmi1+Sox2+ Cells in Driving Recurrence in Prostate Cancer.

Yoo YA, Vatapalli R, Lysy B, Mok H, Desouki MM, Abdulkadir SA.

J Natl Cancer Inst. 2019 Mar 1;111(3):311-321. doi: 10.1093/jnci/djy142.

9.

Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy.

Anker JF, Naseem AF, Mok H, Schaeffer AJ, Abdulkadir SA, Thumbikat P.

Nat Commun. 2018 Apr 23;9(1):1591. doi: 10.1038/s41467-018-03900-x.

10.

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer.

Anker JF, Mok H, Naseem AF, Thumbikat P, Abdulkadir SA.

J Vis Exp. 2018 Mar 6;(133). doi: 10.3791/57301.

11.

Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib.

Carneiro BA, Pamarthy S, Shah AN, Sagar V, Unno K, Han H, Yang XJ, Costa RB, Nagy RJ, Lanman RB, Kuzel TM, Ross JS, Gay L, Elvin JA, Ali SM, Cristofanilli M, Chae YK, Giles FJ, Abdulkadir SA.

Clin Cancer Res. 2018 Jun 15;24(12):2732-2739. doi: 10.1158/1078-0432.CCR-18-0332. Epub 2018 Mar 20.

12.

Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations.

Carneiro BA, Collier KA, Nagy RJ, Pamarthy S, Sagar V, Fairclough S, Odegaard J, Lanman RB, Costa R, Taxter T, Kuzel TM, Fan A, Chae YK, Cristofanilli M, Hussain MH, Abdulkadir SA, Giles FJ.

JCO Precis Oncol. 2018;2. doi: 10.1200/PO.17.00176. Epub 2018 Feb 14.

13.

Organoids model distinct Vitamin E effects at different stages of prostate cancer evolution.

Njoroge RN, Unno K, Zhao JC, Naseem AF, Anker JF, McGee WA, Nonn L, Abdulkadir SA.

Sci Rep. 2017 Nov 24;7(1):16285. doi: 10.1038/s41598-017-16459-2.

14.

Modeling African American prostate adenocarcinoma by inducing defined genetic alterations in organoids.

Unno K, Roh M, Yoo YA, Al-Shraideh Y, Wang L, Nonn L, Abdulkadir SA.

Oncotarget. 2017 Apr 19;8(31):51264-51276. doi: 10.18632/oncotarget.17230. eCollection 2017 Aug 1.

15.

Overcoming immunosuppression in bone metastases.

Reinstein ZZ, Pamarthy S, Sagar V, Costa R, Abdulkadir SA, Giles FJ, Carneiro BA.

Crit Rev Oncol Hematol. 2017 Sep;117:114-127. doi: 10.1016/j.critrevonc.2017.05.004. Epub 2017 May 12. Review.

PMID:
28600175
16.

Bmi1 marks distinct castration-resistant luminal progenitor cells competent for prostate regeneration and tumour initiation.

Yoo YA, Roh M, Naseem AF, Lysy B, Desouki MM, Unno K, Abdulkadir SA.

Nat Commun. 2016 Oct 5;7:12943. doi: 10.1038/ncomms12943.

17.

KAT8 Regulates Androgen Signaling in Prostate Cancer Cells.

Kim JY, Yu J, Abdulkadir SA, Chakravarti D.

Mol Endocrinol. 2016 Aug;30(8):925-36. doi: 10.1210/me.2016-1024. Epub 2016 Jun 7.

18.

PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.

Kirschner AN, Wang J, van der Meer R, Anderson PD, Franco-Coronel OE, Kushner MH, Everett JH, Hameed O, Keeton EK, Ahdesmaki M, Grosskurth SE, Huszar D, Abdulkadir SA.

J Natl Cancer Inst. 2014 Dec 13;107(2). pii: dju407. doi: 10.1093/jnci/dju407. Print 2015 Feb.

19.

Emerging therapeutic targets in bladder cancer.

Carneiro BA, Meeks JJ, Kuzel TM, Scaranti M, Abdulkadir SA, Giles FJ.

Cancer Treat Rev. 2015 Feb;41(2):170-8. doi: 10.1016/j.ctrv.2014.11.003. Epub 2014 Nov 24. Review.

PMID:
25498841
20.

A functional variant in NKX3.1 associated with prostate cancer risk in the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Martinez EE, Darke AK, Tangen CM, Goodman PJ, Fowke JH, Klein EA, Abdulkadir SA.

Cancer Prev Res (Phila). 2014 Sep;7(9):950-7. doi: 10.1158/1940-6207.CAPR-14-0075. Epub 2014 Jun 3.

21.

RNAi screen identifies a synthetic lethal interaction between PIM1 overexpression and PLK1 inhibition.

van der Meer R, Song HY, Park SH, Abdulkadir SA, Roh M.

Clin Cancer Res. 2014 Jun 15;20(12):3211-21. doi: 10.1158/1078-0432.CCR-13-3116. Epub 2014 Apr 25.

22.

Decreased mitochondrial SIRT3 expression is a potential molecular biomarker associated with poor outcome in breast cancer.

Desouki MM, Doubinskaia I, Gius D, Abdulkadir SA.

Hum Pathol. 2014 May;45(5):1071-7. doi: 10.1016/j.humpath.2014.01.004. Epub 2014 Jan 23.

23.

PIM1 kinase as a target in prostate cancer: roles in tumorigenesis, castration resistance, and docetaxel resistance.

Holder SL, Abdulkadir SA.

Curr Cancer Drug Targets. 2014;14(2):105-14. Review.

PMID:
24274399
24.

RAMP1 is a direct NKX3.1 target gene up-regulated in prostate cancer that promotes tumorigenesis.

Logan M, Anderson PD, Saab ST, Hameed O, Abdulkadir SA.

Am J Pathol. 2013 Sep;183(3):951-63. doi: 10.1016/j.ajpath.2013.05.021. Epub 2013 Jul 16.

25.

Selective COX-2 inhibitor (celecoxib) decreases cellular growth in prostate cancer cell lines independent of p53.

Katkoori VR, Manne K, Vital-Reyes VS, Rodríguez-Burford C, Shanmugam C, Sthanam M, Manne U, Chatla C, Abdulkadir SA, Grizzle WE.

Biotech Histochem. 2013 Jan;88(1):38-46. doi: 10.3109/10520295.2012.724713. Epub 2012 Nov 21.

PMID:
23167625
26.

Antioxidant treatment promotes prostate epithelial proliferation in Nkx3.1 mutant mice.

Martinez EE, Anderson PD, Logan M, Abdulkadir SA.

PLoS One. 2012;7(10):e46792. doi: 10.1371/journal.pone.0046792. Epub 2012 Oct 15.

27.

Nkx3.1 and Myc crossregulate shared target genes in mouse and human prostate tumorigenesis.

Anderson PD, McKissic SA, Logan M, Roh M, Franco OE, Wang J, Doubinskaia I, van der Meer R, Hayward SW, Eischen CM, Eltoum IE, Abdulkadir SA.

J Clin Invest. 2012 May;122(5):1907-19. doi: 10.1172/JCI58540. Epub 2012 Apr 9.

28.

Pim1 kinase is required to maintain tumorigenicity in MYC-expressing prostate cancer cells.

Wang J, Anderson PD, Luo W, Gius D, Roh M, Abdulkadir SA.

Oncogene. 2012 Apr 5;31(14):1794-803. doi: 10.1038/onc.2011.371. Epub 2011 Aug 22.

29.

A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53.

Kim J, Roh M, Doubinskaia I, Algarroba GN, Eltoum IE, Abdulkadir SA.

Oncogene. 2012 Jan 19;31(3):322-32. doi: 10.1038/onc.2011.236. Epub 2011 Jun 20.

30.

Tumorigenic polyploid cells contain elevated ROS and ARE selectively targeted by antioxidant treatment.

Roh M, van der Meer R, Abdulkadir SA.

J Cell Physiol. 2012 Feb;227(2):801-12. doi: 10.1002/jcp.22793.

31.

Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.

Kim J, Roh M, Abdulkadir SA.

BMC Cancer. 2010 Jun 1;10:248. doi: 10.1186/1471-2407-10-248.

32.

Targeting the endothelin receptor in prostate cancer bone metastasis: Back to the mouse?

Roh M, Abdulkadir SA.

Cancer Biol Ther. 2010 Apr 15;9(8):615-7. Epub 2010 Apr 26. No abstract available.

33.

Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma.

Wang J, Kim J, Roh M, Franco OE, Hayward SW, Wills ML, Abdulkadir SA.

Oncogene. 2010 Apr 29;29(17):2477-87. doi: 10.1038/onc.2010.10. Epub 2010 Feb 8.

34.

SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress.

Kim HS, Patel K, Muldoon-Jacobs K, Bisht KS, Aykin-Burns N, Pennington JD, van der Meer R, Nguyen P, Savage J, Owens KM, Vassilopoulos A, Ozden O, Park SH, Singh KK, Abdulkadir SA, Spitz DR, Deng CX, Gius D.

Cancer Cell. 2010 Jan 19;17(1):41-52. doi: 10.1016/j.ccr.2009.11.023.

35.

Interactions between cells with distinct mutations in c-MYC and Pten in prostate cancer.

Kim J, Eltoum IE, Roh M, Wang J, Abdulkadir SA.

PLoS Genet. 2009 Jul;5(7):e1000542. doi: 10.1371/journal.pgen.1000542. Epub 2009 Jul 3.

36.

A role for polyploidy in the tumorigenicity of Pim-1-expressing human prostate and mammary epithelial cells.

Roh M, Franco OE, Hayward SW, van der Meer R, Abdulkadir SA.

PLoS One. 2008 Jul 2;3(7):e2572. doi: 10.1371/journal.pone.0002572.

37.

Haploinsufficient prostate tumor suppression by Nkx3.1: a role for chromatin accessibility in dosage-sensitive gene regulation.

Mogal AP, van der Meer R, Crooke PS, Abdulkadir SA.

J Biol Chem. 2007 Aug 31;282(35):25790-800. Epub 2007 Jun 30.

38.

Transgenic mice for Cre-inducible overexpression of the oncogenes c-MYC and Pim-1 in multiple tissues.

Roh M, Kim J, Song C, Wills M, Abdulkadir SA.

Genesis. 2006 Oct;44(10):447-53.

PMID:
17013838
39.
40.

Enhanced EGR1 activity promotes the growth of prostate cancer cells in an androgen-depleted environment.

Yang SZ, Eltoum IA, Abdulkadir SA.

J Cell Biochem. 2006 Apr 15;97(6):1292-9.

PMID:
16552752
41.

Mechanisms of prostate tumorigenesis: roles for transcription factors Nkx3.1 and Egr1.

Abdulkadir SA.

Ann N Y Acad Sci. 2005 Nov;1059:33-40. Review.

PMID:
16382041
42.

Effects of Histone Deacetylase Inhibitor (HDACi); Trichostatin-A (TSA) on the expression of housekeeping genes.

Mogal A, Abdulkadir SA.

Mol Cell Probes. 2006 Apr;20(2):81-6. Epub 2005 Dec 2.

PMID:
16326072
43.

Chromosomal instability induced by Pim-1 is passage-dependent and associated with dysregulation of cyclin B1.

Roh M, Song C, Kim J, Abdulkadir SA.

J Biol Chem. 2005 Dec 9;280(49):40568-77. Epub 2005 Oct 12.

44.

Interaction of Nkx3.1 and p27kip1 in prostate tumor initiation.

Gary B, Azuero R, Mohanty GS, Bell WC, Eltoum IE, Abdulkadir SA.

Am J Pathol. 2004 May;164(5):1607-14.

45.

A novel time-course cDNA microarray analysis method identifies genes associated with the development of cisplatin resistance.

Whiteside MA, Chen DT, Desmond RA, Abdulkadir SA, Johanning GL.

Oncogene. 2004 Jan 22;23(3):744-52.

PMID:
14737109
46.

Overexpression of the oncogenic kinase Pim-1 leads to genomic instability.

Roh M, Gary B, Song C, Said-Al-Naief N, Tousson A, Kraft A, Eltoum IE, Abdulkadir SA.

Cancer Res. 2003 Dec 1;63(23):8079-84.

47.

Notch signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines.

Zayzafoon M, Abdulkadir SA, McDonald JM.

J Biol Chem. 2004 Jan 30;279(5):3662-70. Epub 2003 Nov 5.

48.

Early growth response gene 1 modulates androgen receptor signaling in prostate carcinoma cells.

Yang SZ, Abdulkadir SA.

J Biol Chem. 2003 Oct 10;278(41):39906-11. Epub 2003 Jul 30.

49.
50.

Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia.

Abdulkadir SA, Magee JA, Peters TJ, Kaleem Z, Naughton CK, Humphrey PA, Milbrandt J.

Mol Cell Biol. 2002 Mar;22(5):1495-503.

Supplemental Content

Loading ...
Support Center